Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60% of patients, with approximately 20% discontinuing therapy because of intolerance and approximately 20% developing drug resistance. The advent of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib, has provided multiple options for patients. These agents are more potent, have unique adverse effect profiles, and are more likely to achieve relevant milestones, such as early molecular responses (3-6 months) and optimal molecular responses (12 months). The acquisition of BCR-ABL kinase domain mutations is also reportedly lower with these drugs. Thus far, none of the randomized phase III clinical trials have shown a clinically significant survival difference between frontline imatinib versus newer TKIs. Cost and safety issues with the newer TKIs, such as vascular disease with nilotinib and ponatinib and pulmonary hypertension with dasatinib, have dampened the enthusiasm of using these drugs as frontline options. While the utility of new TKIs in the setting of imatinib failure or intolerance is clear, their use as frontline agents should factor in the age of the patient, additional comorbidities, risk stratification (Sokal score), and cost. Combination therapies and newer agents with potential to eradicate quiescent chronic myeloid leukemia stem cells offers future hope.
C hronic myeloid leukemia (CML) is a clonal, hematopoietic stem cell disorder, characterized by a reciprocal translocation that involves fusion of the Abelson oncogene (ABL) located on chromosome 9q34 with the breakpoint cluster region (BCR) on chromosome 22q11.2. 1 This reciprocal translocation, t(9;22) (q34;q11.2), results in a shortened chromosome 22 called the Philadelphia (Ph) chromosome, which encodes the BCR-ABL1 fusion oncoprotein ( Fig. 1 ). [2] [3] [4] This protein has constitutive tyrosine kinase activity, which stimulates hematopoietic transformation and myeloproliferation. 5 The predominant isoform of BCR-ABL is a 210-kd protein that is present in more than 90% of patients with CML. 6 Prior to the advent of tyrosine kinase inhibitors (TKIs), treatment options for patients with CML were limited to cytoreductive agents, interferon α (IFN-α), and allogeneic stem cell transplantation. 7 The use of cytoreductive agents, such as hydroxyurea, arsenic, and busulfan, was largely palliative (symptom control), bearing no impact on the natural course of the disease. Interferon α was the first agent with disease-modifying effect, with a favorable impact on overall survival (OS). 7 In prospective, randomized studies, IFN-α produced rates of major cytogenetic responses (Mcg) of 11% to 30% and complete cytogenetic responses (CCgR) in approximately 10% of patients. [8] [9] [10] Treatment with IFN-α was, however, limited by poor tolerability and progressive disease. 11 Similarly, although allogeneic stem cell transplant is considered curative, it is associated with high morbidity (acute and chronic graft versus host disease) and mortality (nonrelapse mortality), limiting generalized applicability. 7 In 2003, the first major breakthrough was documented, with the results of the IRIS (International Randomized Study of Interferon and STI571) study demonstrating superiority of imatinib mesylate in comparison to combination therapy with IFN-α and low-dose cytarabine, in patients with chronic phase CML (CP-CML) ( Table 1) . 12 At 18 months, the rates of Mcg and CCgR were 87.1% versus 34.7% and 76.2% versus 14.5% in the imatinib versus combination-therapy arms, respectively. 12 The estimated rate of freedom from progression to accelerated or blast phase CML (accelerated phase [AP] and blast phase [BP]) was 96.7% versus 91.5% in the imatinib versus combination-therapy arm, respectively, and importantly imatinib was better tolerated. 12 The study was designed as a crossover study, and given the success of imatinib, a large proportion of patients (65% [N = 359], 26% due to intolerance to IFN-α) crossed over to the imatinib arm. 13 At the 5-year follow-up 87% of patients had achieved a CCgR, with an estimated OS of 89%. 13 With the use of imatinib, the survival of patients with CP-CML has dramatically improved. However, with time, 20% to 30% of patients develop TKI resistance, commonly attributable to BCR-ABL1 kinase domain mutations. [14] [15] [16] Some patients fail therapy despite inhibition of BCR-ABL1, implicating activation of alternative resistance mechanisms. 15 In addition, 5% to 10% discontinue therapy secondary to poor tolerability. 13 This has led to the development of newer TKIs, such as nilotinib, dasatinib, bosutinib, and ponatinib (Tables 1-3 ). These agents inhibit a spectrum of tyrosine kinases apart from BCR-ABL1 and have differing potencies and adverse effect profiles. In this review, we attempt to discuss the role of newer TKIs in the management of CML.
Imatinib Mesylate
Imatinib mesylate was the first TKI, US Food and Drug Administration (FDA) approved for the management of CML. Imatinib binds to the BCR-ABL1 kinase domain, which is in an inactive conformation in a pocket reserved for the ATP-binding site, thus preventing the transfer of a phosphate group to tyrosine on the protein substrate and the subsequent activation of phosphorylated protein (Fig. 1 ). The pharmacokinetic properties and drug interactions for imatinib are detailed in Table 2, whereas  Table 3 lists the adverse effect profile. At 8 years of follow-up on the IRIS study, 45% of patients had discontinued treatment because of adverse events /safety (6%), unsatisfactory therapeutic outcomes (16%), allogeneic stem cell transplantation (3%), death (3%), or other reasons. 17 The OS rate was 85%, with the annual rates of progression to AP or BP in years 4 to 8 after imatinib therapy being 0.9%, 0.5%, 0%, 0%, and 0.4%, respectively. Progression to AP or BC was noted only in 3% of patients who achieved CCgR and in none of patients who achieved major molecular response (MMR). 17 While conventional response criteria for CML have followed the optimal achievement of a complete hematological response (CHR) by 3 months, CCgR by 9 to 12 months, and an MMR by 18 months (Table 4) , there is increasing data suggesting that the achievement of BCR-ABL1 transcripts of 10% or less at 3 months (early molecular response [EMR]) predicts for better OS, progression-free survival (PFS), cumulative incidence of CCgR, and MMR. 18, 19 This goal seems to be better achieved by second-generation TKI, with a recent study showing that 91.4% of patients receiving dasatinib achieved an EMR. 20 In addition, suboptimal responses to imatinib and intolerance often lead to poor disease control with higher rates of AP or BP.
Imatinib is a highly effective TKI for approximately 60% of CML patients. 21 It is, however, less potent than the second-generation TKIs, an issue that can result in suboptimal kinase inhibition leading to resistance and loss of responses. 22 Nearly all patients experience some impairment in quality of life, such as fluid retention (periorbital and peripheral), muscle cramps, or gastrointestinal disturbances (nausea, vomiting, and diarrhea). 12, 13, 23 However, there are no worrying organ toxicity signals emerging after prolonged therapy with imatinib. The early concerns about an increase in cancer susceptibility and cardiac dysfunction have also not borne out. 24 
Nilotinib
Nilotinib is a more potent analog of imatinib and was approved by the US FDA in 2007 for the treatment of patients with CP or AP CML that were resistant to or intolerant to imatinib. In vitro profiling has demonstrated that nilotinib is effective against most imatinib-resistant Abl kinase domain mutations. Clinically, 5 kinase domain mutations remain of major concern, T315I (gatekeeper mutation), F359V, E255K/V, and Y253H (Table 4 ). 25 These mutations most frequently emerge on frontline or second-line nilotinib therapy, and their presence is a contraindication to the to the formation of an oncogene, which encodes the BCR-ABL1 fusion oncoprotein. This protein has constitutively up-regulated tyrosine kinase activity and by phosphorylation of substrates causes downstream activation of various molecular pathways such as JAK/STAT, PI3K/AKT, RAS/MEK, mTOR, Src kinases. These in turn dysregulate the adhesion, proliferation, transformation, and apoptotic behavior of hematopoietic cells. 5 The BCR-ABL protein has been described as a complex coiled molecular structure with spatial domains: Src-homology 2 (SH2) and SH3 domains, which bind adapter proteins; and the kinase domain which has the ATP, substrate, and allosteric myristate-binding pockets. These different binding sites as well as downstream pathways are potential therapeutic targets for drug development against CML. 87, 88 The Cancer Journal • Volume 22, Number 1, January/February 2016 Tyrosine Kinase Inhibitors and CML (Table 1) . 26 At 12 months, the rates of MMR for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P < 0.001). 26 The rates of CCgR by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%). 26 Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib BID had a significant improvement in the time to progression to AP or BP. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. 26 This study led to the frontline approval of nilotinib in the management of patients with newly diagnosed CML. At the 5-year follow-up of the ENESTnd study, 60%, 62%, and 50% of patients in the nilotinib 300 mg BID, 400 mg BID, and imatinib arms, respectively, remained on core treatment. 27, 28 More than half of patients in the nilotinib arms achieved MR 4.5 (BCR-ABL IS ≤0.0032%) by 5 years. Rates of MMR, freedom from progression to AP and BP, and OS were higher with nilotinib in comparison to imatinib. An emerging concern related to the use of nilotinib is the occurrence of vascular events including peripheral arterial occlusive disease (PAOD), coronary artery disease (CAD), cerebrovascular disease (CVA), hyperglycemia, and hypercholesterolemia. 27, 28 In the ENESTnd trial, 20% of patients on the nilotinib 300 mg arm who were not diabetic at baseline were diabetic by 3 years, in comparison to 9% on the imatinib arm. 29 
Dasatinib
Dasatinib is a second-generation BCR-ABL1 inhibitor that has a 325-fold higher potency in vitro in comparison to imatinib. Dasatinib is active against the majority of the kinase domain mutations, with the exception of the T315I gatekeeper mutation. 30 In the CA180-034 trial of patients with imatinib-resistant or imatinib-intolerant CP-CML, dasatinib 100 mg once daily showed durable efficacy and safety, including a 6-year PFS of 49%, OS of 71%, and cumulative MMR rate of 43%. 31 In the phase III DASISION (DASatinib versus Imatinib Study In treatment-Naive CML patients) trial, patients with newly diagnosed CP-CML were randomized to receive dasatinib 100 mg (n = 259) or imatinib 400 mg (n = 260) once daily (Table 1) . 32 Cumulative response rates by 24 months in dasatinib and imatinib arms were CCgR in 86% versus 82%, MMR in 64% versus 46%, and MR 4.5 in 17% versus 8%. 33 Transformation to AP/BP CML on study occurred in 2.3% with dasatinib versus 5.0% with imatinib. In safety analyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasatinib compared with imatinib, whereas pleural effusion and grade 3/4 thrombocytopenia were more frequent with dasatinib. 33 This trial led to the frontline approval of dasatinib for patients with newly diagnosed disease with CP-CML. At 4 years, 76% of patients on the dasatinib arm and 63% of patients on the imatinib arm had achieved an MMR. 34 In patients who achieved MMR, the median time to MMR for dasatinib and imatinib patients was 9.2 and 15.0 months, respectively. Through 4 years, transformation to AP and BP occurred in 12 patients receiving dasatinib and 18 patients receiving imatinib. Progression-free survival at 4 years was 90% in both arms and OS was 93% and 92% for dasatinib and imatinib, respectively. 34 At 3 months, 84% of dasatinib-treated patients versus 64% of imatinib-treated patients achieved an EMR. In the dasatinib arm, PFS and OS rates at 4 years for patients who had BCR-ABL 10% or less at 3 months versus those who did not were 92% versus 67% (P = 0.0004) and 95% versus 83% (P = 0.0092), respectively. In the imatinib arm, PFS and OS rates at 4 years for patients who had BCR-ABL 10% or less at 3 months versus those who did not were 95% versus 70% (P < 0.0001) and 96% versus 84% (P = 0.0021), respectively. Most drug-related adverse events occurred within the first year of treatment and included myelosuppression, fluid retention (pleural effusion and superficial localized edema), diarrhea, headache, musculoskeletal pain, rash, and nausea. Of more concern are reports of pulmonary arterial hypertension, which by and large seems to resolve in most patients after discontinuing the medication. 34 
Bosutinib
Bosutinib is an oral Src/Abl TKI. The phase III BELA (Bosutinib Efficacy and Safety in Newly Diagnosed CML) trial compared bosutinib with imatinib in newly diagnosed CP-CML (Table 1) . 35 A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg/d or imatinib 400 mg/d. The CCgR rate at 12 months was not different for bosutinib (70%; 95% confidence interval [CI], 64%-76%) versus imatinib (68%; 95% CI, 62%-74%; 2-sided P = 0.601); hence, the study did not achieve its primary endpoint. 35 The MMR rate at 12 months was higher with bosutinib (41%; 95% CI, 35%-47%) compared with imatinib (27%; 95% CI, 22%-33%; 2-sided P < 0.001). Time to CCgR and MMR was faster with bosutinib compared with imatinib (2-sided P < 0.001 for both). On-treatment transformation to AP/BP occurred in 4 patients (2%) on bosutinib compared with 10 patients (4%) on imatinib. The safety profiles of bosutinib and imatinib were distinct; gastrointestinal and liver-related events were more frequent with bosutinib, whereas neutropenia, musculoskeletal disorders, and edema were more frequent with imatinib. Bosutinib, compared with imatinib, was associated with higher incidences of diarrhea (68% vs 21%, respectively), vomiting (32% vs 13%, respectively), and abdominal pain (11% vs 5%, respectively). 35 Conversely, bosutinib, compared with imatinib, was associated with lower incidences of edema (11% vs 38%, respectively), bone pain (4% vs 10%, respectively), and muscle spasms (2% vs 20%, respectively). The aggregate incidence of grade 3 or 4 AEs was 64% in the bosutinib arm and 48% in the imatinib arm (P < 0.001). 35 
Ponatinib
Ponatinib, a highly potent third-generation TKI, was granted accelerated approval by the US FDA in December 2012 for the treatment of patients with CML that were resistant to, or intolerant of, prior TKI therapy. Ponatinib is effective against a vast spectrum of kinase domain mutations, including the T315I gatekeeper mutation. 36 In a phase II study (PACE [Ponatinib in patients with CML or Ph + ALL]), among 267 patients with CP-CML, 56% had an Mcg response (including 70% of patients with the T315I mutation), 46% had a CCgR (66% with the T315I mutation), and 34% had an MMR (56% of patients with the T315I mutation). 37 Responses were observed regardless of the baseline kinase domain mutation status. No single BCR-ABL1 mutation conferring resistance to ponatinib was detected. Among 83 patients with AP-CML and 62 with BP-CML, 55% and 23% had an Mcg response. Common adverse events reported were thrombocytopenia (37%), rash (34%), dry skin (32%), and abdominal pain (22%). Serious arterial thrombotic events were observed in 9% of patients; these events were considered to be treatment related in 3%. 37 Additional follow-up from these ponatinib trials has since revealed a much higher frequency of serious adverse vascular events (48% and 24% in the phases I and II trials, respectively). 38 This concern led the US FDA and Ariad Pharmaceuticals to abruptly withdraw ponatinib from the market in October 2013. Importantly, an ongoing phase III trial (EPIC [Exploring Ponatinib In untreated patients with CML]) comparing ponatinib to imatinib for the first-line treatment of CML was also closed, patients were crossed over to imatinib, and their follow-up was terminated. 38 of MMR Mutations CCA/Ph+ *Defined as white blood cells less than 10 Â 10 9 /L, basophils less than 5%, no myelocytes, promyelocytes, myeloblasts in the differential, platelet count less than 450 Â 10 9 /L, spleen nonpalpable.
†Defined as 1 to 35% Ph + metaphases. In January 2014, the US FDA allowed Ariad Pharmaceuticals to resume the marketing of ponatinib with new safety measures. The current indications for ponatinib include treatment of adult patients with T315I-positive CML (CP, AP, and BP) or T315I-positive Ph + ALL, and the treatment of adult patients with CP, AP, or BP CML or Ph + ALL for whom no other TKI therapy is indicated. The warnings and precautions in the label were revised to describe the vascular occlusion events, including venous thromboembolism, PAOD, CAD, and CVA. The optimal starting dose for ponatinib was decreased to 30 mg daily. Additional adverse effects include pancreatitis (biochemical and clinical), hepatic transaminitis, and treatment-emergent hypertension ( Table 3 ).
Choosing the Optimal TKI
Imatinib was the first TKI approved for the management of CML and has more than 15 years of safety and efficacy data associated with it. 24 It is generally well tolerated, and all the randomized studies comparing imatinib with second-generation TKIs have not demonstrated a clinically significant survival difference (both for OS and PFS). Therefore, while considering frontline therapy in patients in whom survival is the predominant goal, imatinib still remains an excellent option. This is especially relevant if patients have a low Sokal score or a low EUTOS (European Treatment and Outcome Study Score) score. 39 One strategy designed to maximize the use of imatinib and use only more potent TKIs where there is evidence of a high risk of progression is to use frontline imatinib and rely on the molecular responses at 3 and/ or 6 months to identify the high-risk patients and switch them to a second-generation TKI (lack of EMR at 3-6 months or lack of an optimal molecular response at 12 months). This concept is supported in part by the recent TIDEL-II (Therapeutic Intensification in De Novo Leukemia II) study. Two hundred ten patients with CP-CML were enrolled in 2 equal, sequential cohorts. 40 All patients started treatment with imatinib 600 mg/d. Imatinib plasma trough level was performed at day 22, and if less than 1000 ng/mL, the dose of imatinib was escalated to 800 mg/d. Patients were then assessed against molecular targets: BCR-ABL1 10% or less, 1% or less, and 0.1% or less at 3, 6, and 12 months, respectively. Cohort 1 patients failing any target escalated to imatinib 800 mg/d and subsequently switched to nilotinib 400 mg BID for failing the same target 3 months later. Cohort 2 patients failing any target were switched to nilotinib directly, as did patients with intolerance or loss of response in either cohort. At 2 years, 55% of patients remained on imatinib, and 30% on nilotinib. Only 12% had greater than 10% BCR-ABL1 at 3 months. Confirmed MMR was achieved in 64% at 12 months and 73% at 24 months. At 3 years, OS was 96%, and transformation-free survival was 95%. 40 In contrast to imatinib, the frontline use of second-generation TKIs results in faster and deeper molecular responses (MMR/ MR 3 and MR 4.5 ), 26, 33, 41 lower risks of AP/BC transformation, 33 and, in the case of nilotinib, lower risk of acquired kinase domain mutations. 22 Hence, these agents can be used preferentially in younger patients and in those with high Sokal or EUTOS scores (studies need further validation). However, outstanding questions remain over the long-term safety profile of these drugs. The development of vascular adverse effects such as PAOD, CVA, CAD, and venous thromboembolism with nilotinib and ponatinib and cardiopulmonary toxicities such as pleural effusions, interstitial pneumonitis, and pulmonary hypertension with dasatinib warrants caution while prescribing these agents for frontline therapy. These toxicities may, in part, contribute to the lack of significant differences in OS between patients treated with imatinib and those receiving second-generation TKIs.
Newer TKIs have a distinct role in patients who have known mutations precluding the use of imatinib or other secondgeneration TKIs (Table 5 ) and in the setting of intolerance to imatinib therapy. Comorbidities of the patient and adverse effect profile of the TKI of interest should be an important consideration in decision making. For example, nilotinib and ponatinib should be avoided in someone who has preexisting peripheral vascular disease or cardiovascular disease, whereas dasatinib should be avoided in someone with preexisting pleural effusions or pulmonary hypertension. At present, the cost of second-generation TKIs is not remarkably different from imatinib. However, the patent for imatinib is expected to expire soon, and it will be available as a generic product. Clinicians then need to weigh the advantages some patients gain with nilotinib or dasatinib in the frontline setting against the difference in cost. 42 Newer Agents for CML Although TKIs have offered much in terms of OS and quality of life for patients with CML, the ability of these agents to cure CML is limited. In the prospective, multicenter, Stop Imatinib (STIM) study, imatinib treatment (of >2 years' duration) was discontinued in patients with CML who had molecularly undetectable leukemia (complete molecular response [CMR] = >5-log reduction in BCR-ABL). One hundred patients were enrolled, and 69 patients had at least 12 months' follow-up. Forty-two (61%) of these 69 patients had a relapse. 43 At 12 months, the probability of persistent CMR for these 69 patients was 41% (95% CI, 29%-52%). All patients who had a relapse responded to reintroduction of imatinib. 43 This failure results from the inability of TKIs to eradicate quiescent CML stem cells. In a recent study, the activation of peroxisome proliferator-activated receptor γ by glitazones (antidiabetic drugs) decreased the expression of STAT5 and its downstream targets HIF2α and CITED2, which are key guardians of quiescence in stem cells. 44 When pioglitazone was given temporarily to 3 patients with CML with chronic residual disease despite imatinib therapy, all of them achieved sustained CMRs up to 4.7 years after withdrawal of pioglitazone. 44 These exciting results need validation in larger prospective studies. Newer TKIs with higher potencies and activity against the gatekeeper mutation, such as danusertib (PHA-739358) [45] [46] [47] and rebastinib (DCC-2036), are undergoing clinical development ( Table 6 ). ABL001 is a potent, specific BCR-ABL inhibitor with a distinct, allosteric mechanism of action that recently entered phase I development. 48 It has been developed for use in combination with nilotinib to provide greater coverage of BCR-ABL and in order to avoid the development of resistance. In contrast to TKIs that bind to the ATP site of the ABL1 kinase domain, ABL001 binds to a pocket on the BCR-ABL kinase domain that is normally occupied by the myristoylated N-terminus of ABL1 (Fig. 1) . ABL001 functionally mimics the role of the myristoylated N-terminus by occupying its vacant binding site and restores the negative regulation of the kinase activity. 48 Given that it does not act on the ATPbinding site of the kinase domain, it has demonstrable in vitro activity against the T315I gatekeeper mutation.
Summary
Tyrosine kinase inhibitors have revolutionized the management of patients with CML and have markedly improved their OS. Imatinib was the first TKI approved and is currently considered a very effective frontline option for most patients. With more than a decade of safety data, the long-term use of imatinib is generally safe, and no major safety concerns have emerged. With time, a fair number of patients discontinue imatinib, either because of disease progression/resistance or secondary to intolerance. For this group of patients, newer TKIs have revolutionized care. The newer TKIs are more potent than imatinib and have unique adverse effect profiles. These agents are more likely than imatinib to achieve optimal molecular responses, especially EMR, leading to a considerable debate on which TKI is the best frontline option. Although there is no doubt on their efficacy, especially in patients with kinase domain mutations, their safety profiles are somewhat controversial and continue to evolve. Serious vascular adverse effects such as PAOD, CVA, and CAD with nilotinib and ponatinib and the development of pulmonary hypertension with dasatinib currently continue to dampen the enthusiasm for using these drugs as frontline agents. Newer TKIs with enhanced potencies and safety profiles and drugs acting at alternate sites optimizing responses are exciting prospects. 
